XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Balance Sheet Details
6 Months Ended
Jun. 30, 2024
Balance Sheet Details  
Balance Sheet Details

6. Balance Sheet Details

Property and Equipment

Property and equipment as of June 30, 2024 and December 31, 2023 consisted of the following (in thousands):

    

June 30, 2024

    

December 31, 2023

Laboratory equipment

$

21,225

$

19,678

Furniture and fixtures

817

817

Office and computer equipment

 

438

 

438

Leasehold improvements

 

3,447

 

3,447

Total

25,927

24,380

Less: accumulated depreciation

 

(12,453)

 

(11,821)

Property and equipment, net

$

13,474

$

12,559

Depreciation and amortization expense totaled $0.3 million and $0.2 million for the three months ended June 30, 2024 and 2023, and $0.6 and $0.5 million for the six months ended June 30, 2024 and 2023, respectively. Construction in progress and fixed assets not in use were $9.6 million and $8.1 million as of June 30, 2024 and December 31, 2023, respectively, and are included in the laboratory equipment in the table above. These assets are not depreciated until they are placed in service.

Other receivables

Other receivables as of June 30, 2024 and December 31, 2023 consisted of the following (in thousands):

June 30, 2024

    

December 31, 2023

Tenant improvement allowance receivable (Note 12)

$

748

$

1,835

Grant and award receivable (Note 13)

494

1,528

$

1,242

$

3,363

Accounts payable and accrued liabilities

Accounts payable and accrued liabilities as of June 30, 2024 and December 31, 2023 consisted of the following (in thousands):

June 30, 2024

    

December 31, 2023

Accounts payable

$

1,743

$

1,585

Accrued clinical trial expenses

1,680

3,021

Other accrued expenses

428

1,083

$

3,851

$

5,689